JPWO2023049299A5 - - Google Patents
Info
- Publication number
- JPWO2023049299A5 JPWO2023049299A5 JP2024518410A JP2024518410A JPWO2023049299A5 JP WO2023049299 A5 JPWO2023049299 A5 JP WO2023049299A5 JP 2024518410 A JP2024518410 A JP 2024518410A JP 2024518410 A JP2024518410 A JP 2024518410A JP WO2023049299 A5 JPWO2023049299 A5 JP WO2023049299A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- item
- composition
- uridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025171713A JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247236P | 2021-09-22 | 2021-09-22 | |
| US63/247,236 | 2021-09-22 | ||
| US202163255333P | 2021-10-13 | 2021-10-13 | |
| US63/255,333 | 2021-10-13 | ||
| US202263389679P | 2022-07-15 | 2022-07-15 | |
| US63/389,679 | 2022-07-15 | ||
| PCT/US2022/044453 WO2023049299A2 (en) | 2021-09-22 | 2022-09-22 | Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171713A Division JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534575A JP2024534575A (ja) | 2024-09-20 |
| JPWO2023049299A5 true JPWO2023049299A5 (https=) | 2025-10-21 |
| JP2024534575A5 JP2024534575A5 (https=) | 2025-10-21 |
Family
ID=85721146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518410A Pending JP2024534575A (ja) | 2021-09-22 | 2022-09-22 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
| JP2025171713A Pending JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171713A Pending JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240390520A1 (https=) |
| EP (1) | EP4405470A2 (https=) |
| JP (2) | JP2024534575A (https=) |
| KR (2) | KR20250160515A (https=) |
| AU (1) | AU2022349449A1 (https=) |
| CA (1) | CA3232742A1 (https=) |
| GB (3) | GB2700667A (https=) |
| IL (1) | IL311607A (https=) |
| MX (1) | MX2024003570A (https=) |
| WO (1) | WO2023049299A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4545544A3 (en) * | 2015-06-29 | 2025-10-08 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
| CN121555430A (zh) | 2018-05-11 | 2026-02-24 | 比姆医疗股份有限公司 | 使用可编程碱基编辑器系统取代病原性氨基酸的方法 |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| WO2020168122A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2023240076A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2025137465A1 (en) * | 2023-12-21 | 2025-06-26 | Beam Therapeutics Inc. | Base editors with modified editing windows |
| WO2025167914A1 (zh) * | 2024-02-07 | 2025-08-14 | 益杰立科新加坡有限公司 | 通过表观编辑多靶点治疗疾病的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691750B2 (en) * | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| EP3250691B9 (en) * | 2015-01-28 | 2023-08-02 | Caribou Biosciences, Inc. | Crispr hybrid dna/rna polynucleotides and methods of use |
| JP7109784B2 (ja) * | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
-
2022
- 2022-09-22 AU AU2022349449A patent/AU2022349449A1/en active Pending
- 2022-09-22 GB GB2509407.9A patent/GB2700667A/en active Pending
- 2022-09-22 JP JP2024518410A patent/JP2024534575A/ja active Pending
- 2022-09-22 MX MX2024003570A patent/MX2024003570A/es unknown
- 2022-09-22 KR KR1020257035760A patent/KR20250160515A/ko active Pending
- 2022-09-22 KR KR1020247013385A patent/KR20240099200A/ko active Pending
- 2022-09-22 GB GBGB2509406.1A patent/GB202509406D0/en active Pending
- 2022-09-22 CA CA3232742A patent/CA3232742A1/en active Pending
- 2022-09-22 IL IL311607A patent/IL311607A/en unknown
- 2022-09-22 WO PCT/US2022/044453 patent/WO2023049299A2/en not_active Ceased
- 2022-09-22 EP EP22873600.5A patent/EP4405470A2/en active Pending
- 2022-09-22 GB GB2405381.1A patent/GB2628238A/en active Pending
-
2024
- 2024-03-21 US US18/611,988 patent/US20240390520A1/en active Pending
-
2025
- 2025-10-10 JP JP2025171713A patent/JP2026012737A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7765837B2 (ja) | シュタルガルト病の処置におけるヌクレオチド脱アミノ化のためのアンチセンスオリゴヌクレオチド | |
| US20250154504A1 (en) | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia | |
| US20220127609A1 (en) | Antisense oligonucleotides for nucleic acid editing | |
| EP1737879B1 (en) | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides | |
| UA130104C2 (uk) | Композиції на основі ліпідних наночастинок | |
| CA3118559A1 (en) | Lipid nanoparticle formulations | |
| JP2008512097A (ja) | アプタマー医薬品化学 | |
| GB2628238A (en) | Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treatment of disease | |
| JP2002511851A (ja) | 肝細胞の遺伝的病変を修正するためのリコンビナジェニックオリゴヌクレオ塩基のｉｎ ｖｉｖｏでの使用 | |
| JPWO2023049299A5 (https=) | ||
| CN120129532A (zh) | 稳定的脂质或类脂质纳米颗粒悬浮液 | |
| JP2008512098A (ja) | フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用 | |
| JP2025527583A (ja) | 脂質ナノ粒子の組成物 | |
| EP3420093B1 (en) | Micelle based system nuclease encapsulation for in-vivo gene editing | |
| EP4688143A1 (en) | Antisense oligonucleotides for the treatment of liver disease | |
| JPWO2022256440A5 (https=) | ||
| US20220288237A1 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression | |
| JP2026508879A (ja) | 治療用オリゴヌクレオチドの局所送達 | |
| JPWO2021195467A5 (https=) | ||
| CN118109463B (zh) | 靶向PCSK9基因的siRNA及其应用 | |
| Zhou et al. | Case study of antisense oligonucleotides for duchenne muscular dystrophy | |
| WO2026052111A1 (zh) | 一种多聚mRNA | |
| KR20260052816A (ko) | 치료학적 올리고뉴클레오티드의 국소 전달 | |
| WO2025155911A1 (en) | Antisense oligonucleotides for the treatment of hurler syndrome | |
| WO2025165840A1 (en) | Compositions and methods of treating cardiovascular disease |